Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab

Part of paid clinical trials in Huntington Beach, California.

Sponsor
Hanscom, Thomas, M.D.
Study ID
NCT01471691
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Branch Retinal Vein Occlusion
  • Central Retinal Vein Occlusion
  • Macular Edema

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study examines two doses of Ranibizumab (0.5mg and 1.0mg) for the treatment of macular edema secondary to retinal vein occlusion in patients that have previously failed treatment with other macular edema treatments including bevacizumab.

Key Dates

First listed
Nov 16, 2011
Start date
Nov 30, 2011
Status verified
Apr 2015
Primary completion
Feb 28, 2014
Completion
Feb 28, 2014

Study Design

Enrollment
14 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: intravitreal ranibizumab 0.5mg
  • Experimental: intravitreal ranibizumab 1.0mg

Primary Outcome Measure

Mean Change From Baseline BCVA [ Time Frame: Baseline to month 6 ]

Locations (4)

FacilityCityStateZIPSite coordinators
South Coast RetinaHuntington BeachCalifornia92647-
South Coast RetinaLong BeachCalifornia90807-
Thomas Hanscom AMCSanta MonicaCalifornia90404-
South Coast RetinaTorranceCalifornia90505-

Find similar trials in Huntington Beach, CA

By research site
South Coast Retina· Huntington Beach, CASouth Coast Retina· Long Beach, CAThomas Hanscom AMC· Santa Monica, CASouth Coast Retina· Torrance, CA

Related Studies